Workflow
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
NTLAIntellia Therapeutics(NTLA) ZACKS·2024-11-08 15:50

Intellia Therapeutics, Inc. (NTLA) incurred third-quarter 2024 loss of 1.34pershare,whichwasnarrowerthantheZacksConsensusEstimateofalossof1.34 per share, which was narrower than the Zacks Consensus Estimate of a loss of 1.37. In the year-ago quarter, Intellia had incurred a loss of 1.38pershare.Thecompany’stotalrevenuescurrentlycompriseonlycollaborationrevenues.Intelliareportedrevenuesof1.38 per share.The company’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of 9.1 million for the third quarter of 2024 compared with 12millionreportedintheyear−agoquarter.RevenueshoweverbeattheZacksConsensusEstimateof12 million reported in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of 8 million.The ...